316TiP - BREAKOUT: a cross-sectional, prospective, observational study of germline BRCA mutation (gBRCAm) prevalence and real-world outcomes among patients...

Date 11 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Breast Cancer, Metastatic
Breast Cancer
Pathology/Molecular Biology
Presenter Tapashi Dalvi
Citation Annals of Oncology (2017) 28 (suppl_5): v74-v108. 10.1093/annonc/mdx365
Authors T. Dalvi1, K.A. Gelmon2, R. Dent3, M. Pegram4, S. Loibl5, Y. Tazir6, A. Milner7, J. Lewis8
  • 1Medical Evidence And Observational Research, AstraZeneca, 20878 - Gaithersburg/US
  • 2Department Of Medical Oncology, British Columbia Cancer Agency, V5Z 4E6 - Vancouver/CA
  • 3Division Of Medical Oncology, National Cancer Centre Singapore, Duke-NUS Medical School, Singapore/SG
  • 4Breast Cancer Oncology Program, Stanford Women's Cancer Center, Palo Alto/US
  • 5Medicine And Research, German Breast Group, Neu-Isenburg/DE
  • 6Medical Evidence And Observational Research, AstraZeneca, Wedel/DE
  • 7Biostatistics And Information Sciences, AstraZeneca, Cambridge/GB
  • 8Global Medicines Development, AstraZeneca, CB2 1PG - Cambridge/GB

Abstract

Background

Several poly (ADP-ribose) polymerase (PARP) inhibitor therapies are currently under investigation to assess their potential for the management of breast cancer. Olaparib (Lynparza) is being evaluated in a Phase III study in HER2-ve mBC pts with a gBRCAm (OlympiAD; D0819C00003; NCT02000622). The prevalence of germline and somatic BRCA mutations or other somatic homologous recombination repair gene mutations (HRRm) in HER2-ve mBC pts is not well defined. Treatment and clinical outcomes data for pts with HRRm are also limited. The primary objective of this real-world evidence study (NCT03078036) is to estimate gBRCAm prevalence in a population of HER2-ve mBC pts not selected by phenotype, age or family history. Treatment patterns and survival outcomes for pts with HRRm will also be examined.

Trial design

BREAKOUT is a prospective, cross-sectional, non-interventional, observational cohort study recruiting HER2-ve mBC pts who have started first-line chemotherapy within 90 days prior to enrollment. If hormone receptor positive, eligible pts will have exhausted all hormone therapy options prior to enrollment and will not have received prior PARP inhibitor treatment. If unavailable from medical records, gBRCAm status will be locally determined by blood test and, if negative, archival tumor specimens may be examined with a FoundationOne Dx genomic profile. Pts with a gBRCAm, somatic BRCA mutation or other HRRm (in ATM, RAD51B, RAD51C, RAD51D, RAD54L, BRIP1, FANCL, PALB2, BARD1, CHEK1, CHEK2, CDK12 or PPP2R2A) will be followed for ≥18 months to determine the distribution of standard-of-care treatments, progression-free survival (investigator assessed) and overall survival by line of therapy. Approximately 2000 women in 17 countries in North America, the EU and the Asia Pacific region will be enrolled to provide a global gBRCAm prevalence estimate with a precision of no more than ±2%. An interim analysis focusing on gBRCAm prevalence will be carried out once testing has been completed for all pts. The study is expected to conclude in 2019.

Clinical trial identification

NCT03078036, June 2020

Legal entity responsible for the study

AstraZeneca

Funding

AstraZeneca

Disclosure

T. Dalvi: Employee of MedImmune and AstraZeneca, stock ownership in AstraZeneca, Bristol-Myers Squibb, Roche, Achillion, Medivation, Inovio and Gilead. K.A. Gelmon: Consulting fees from Novartis, Pfizer, AstraZeneca, Merck, Genentech and Nanostring. R. Dent: Honoraria and consulting fees from AstraZeneca, Merck, Pfizer, Roche and Eisai, and travel and accommodation expenses from Pfizer. M. Pegram: Received consulting fees from Pfizer, Genentech and Amgen. Y. Tazir, A. Milner, J. Lewis: Employee of AstraZeneca. All other authors have declared no conflicts of interest.